Entheon Biomedical Corp. (CSE:ENBI)

Entheon Biomedical Cash Flow Statement

Financials in millions CAD. Fiscal year is December - November.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020
Net Income	-0.32	-0.3	-8.52	-8.89	-4.38
Depreciation & Amortization	-	-	-0.65	-0.45	0
Other Amortization	-	-	0.65	0.45	-
Loss (Gain) From Sale of Assets	-	-	0	-	-
Loss (Gain) From Sale of Investments	-	-0	0.07	-0.21	-0.05
Stock-Based Compensation	-	0	0.09	2.55	-
Other Operating Activities	-	-	6.46	0.89	2.79
Change in Accounts Receivable	0	0.04	-0.01	0.08	-0.07
Change in Accounts Payable	-0.05	-0.07	-0.63	0.01	-0.21
Change in Other Net Operating Assets	0.01	-0.02	1.08	0.39	-0.92
Operating Cash Flow	-0.36	-0.36	-1.95	-5.33	-2.84
Capital Expenditures	-	-	-	-	-0.01
Cash Acquisitions	-	-	-	-	1.15
Investment in Securities	-	0	0.63	-0.38	-
Other Investing Activities	-	0.02	-0.05	-	-0.06
Investing Cash Flow	-	0.02	0.59	-0.38	1.08
Short-Term Debt Repaid	-	-	-	-	-0
Total Debt Repaid	-	-	-	-	-0
Net Debt Issued (Repaid)	-	-	-	-	-0
Issuance of Common Stock	-	-	-	5.11	4.43
Other Financing Activities	0.15	-	-	-0.13	-
Financing Cash Flow	0.15	-	-	4.98	4.43
Net Cash Flow	-0.21	-0.34	-1.37	-0.74	2.67
Free Cash Flow	-0.36	-0.36	-1.95	-5.33	-2.85
Free Cash Flow Margin	-	-143.79%	-1030.49%	-	-
Free Cash Flow Per Share	-0.05	-0.06	-0.33	-0.98	-1.04
Levered Free Cash Flow	-0.25	-0.25	-1.7	-1.97	-1.94
Unlevered Free Cash Flow	-0.25	-0.25	-1.7	-1.97	-1.94
Change in Net Working Capital	0.04	0.06	-0.32	-0.61	0.91

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.